Media Contact

Career growth can look different for everyone. A good reminder from Yazmin García, Manager, Medical Affairs in Mexico, to focus on your own development, keep learning and give yourself time to grow. At ICON, we believe...

Emerging approaches to first-in-human studies are helping sponsors obtain meaningful clinical insights sooner through integrated study designs, stronger patient engagement, and strategic biomarker implementation. In thi...

EHDS represents a major milestone in European health data governance. Learn how CROs are evolving from data custodians to regulated data users, and what this means for the future of real-world evidence generation. Read...

As AI adoption accelerates across healthcare, ensuring transparency, reproducibility, and scientific rigour remains essential. ICON discusses how organisations can apply AI and machine learning to real-world oncology dat...

Because patients can’t wait, every rare disease development decision matters. Meet ICON at World Orphan Drug Congress Europe, booth \#313, to discuss how our integrated development and regulatory strategy, patient advoca...

Meet with ICON's Clinical Pharmacology team at the 2026 ACCP Annual Meeting and discover new insights from our poster, "siRNA oligonucleotide metabolites: From nuclease processing to pharmacodynamic and adverse events." ...

Join ICON's presentation at WorldCDx on 8 October to explore the common pitfalls that can derail precision medicine initiatives and learn practical approaches for building robust, globally deployable biomarker and compan...

ICON is proud to sponsor the World Patient Safety Congress, from 14 –15 October in Boston. As a global leader in pharmacovigilance, ICON partners with organisations of all sizes to strengthen patient safety strategies a...

Effective pediatric oncology trials depend on strong partnerships across sponsors, sites and CROs. For #ChildhoodCancerAwarenessMonth, ICON’s Jacqui Whiteway and Melanie Villanueva explore how collaboration can help add...

How can medtech companies reduce packaging while maintaining protection, functionality and compliance? In the fourth and final article in MedTech Insight’s PPWR series, ICON's SMEs discuss why packaging minimisation is ...

Blood‑based biomarkers are reshaping Alzheimer’s trials by enabling earlier, cheaper identification. Could these enrolment strategies translate to other slow‑progressing diseases? ICON experts share their insight in the ...

For global clinical trials, localisation, translation availability and linguistic validation can all affect when and how a clinical outcome assessment can be implemented across countries. Yet these considerations are o...